MINIMUM ENTRY REQUIREMENTS
The minimum requirements for admission to any Undergraduate degree programme are:
- Uganda Certificate of Education (UCE) or its equivalent with at least 5 passes
- Uganda Advanced Certificate of Education (UACE) or its equivalent with at least 2 principal passes.
- Diploma holders must have passed with at least a credit.
The minimum requirements for admission to any Diploma programme are:
- Uganda Certificate of Education (UCE) or its equivalent with at least 5 passes
- Uganda Advanced Certificate of Education (UACE) or its equivalent with at least 1 principal pass and two subsidiary passes.
Additionally, for international applicants:
- Applicants whose first language or medium of instruction is not English, must provide evidence from a recognized English language training institution that they have sufficient command of English language.
- Applicants should have their documents equated by Uganda National Examinations Board (UNEB) of UCE and UACE documents and Uganda National Council for Higher Education (UNCHE) for Diploma and Certificate documents.
Bachelor of Pharmacy (Duration 4 years)
Direct Entry
Two principal passes in Biology and Chemistry and at least Subsidiary Pass in either Physics or Mathematics
Diploma Entry
Diploma in Pharmacy.
Should have passed Biology, Chemistry, Mathematics and English at O’ Level with at least a credit.
Sit and pass an entrance examination consisting of three written papers in Pharmacology, Pharmaceutics, Pharmaceutical Chemistry, Natural products, Introduction to Dispensing and Physiology
No | Code | PROGRAMME | DURATION | UGANDAN STUDENTS | INTERNATIONAL STUDENTS | ||
TUITION (SHS.) per Semester | FUNCTIONAL FEES (SHS.) per year | TUITION (SHS.) per Semester | FUNCTIONAL FEES (SHS.) per year | ||||
5 | PHA | Bachelor of Pharmacy | 4 | 1,344,000 | 520,000 | 2,688,000 | 1,040,000 |
Modules for BACHELOR OF PHARMACY V2023 | ||||||||||||||||||||
module_code | module_title | progcode | progversion | practical_hrs | lecture_hrs | contact_hrs | contribution_alg | specialization_code | subject_code | no_of_assessment_types | credit_units | module_level | module_year | module_sem | grading_id | clinical_hrs | added_by | last_modified_by | last_modified_by | last_modified_date |
11 | ||||||||||||||||||||
AN1111 | SYSTEMIC ANATOMY I | PHA | V2023 | 16 | 52 | 60 | PERCENT | 2 | 4 | core | 1 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BCH1121 | INTRODUCTORY BIOCHEMISTRY | PHA | V2023 | 18 | 45 | 60 | PERCENT | 2 | 4 | core | 1 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH1121 | BASIC ORGANIC AND INORGANIC CHEMISTRY | PHA | V2023 | 30 | 45 | 60 | PERCENT | 2 | 4 | core | 1 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH1122 | BASIC PHARMACY SKILLS | PHA | V2023 | 30 | 28 | 45 | PERCENT | 2 | 3 | core | 1 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
CSC1111 | COMPUTER SKILLS | PHA | V2023 | 32 | 29 | 45 | PERCENT | 2 | 3 | core | 1 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
DVS1106 | INTRODUCTION TO POLITICAL ECONOMY | PHA | V2023 | 0 | 45 | 45 | PERCENT | 2 | 3 | core | 1 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
PHS1121 | PHYSIOLOGY I | PHA | V2023 | 15 | 60 | 75 | PERCENT | 2 | 5 | core | 1 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
12 | ||||||||||||||||||||
ANA1221 | SYSTEMIC ANATOMY II | PHA | V2023 | 20 | 50 | 60 | PERCENT | 2 | 4 | core | 1 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BCH1221 | MOLECULAR BIOLOGY, ONCOGENESIS & IMMUNOLOGY | PHA | V2023 | 14 | 45 | 60 | PERCENT | 2 | 4 | core | 1 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BCH1222 | MEDICAL BIOCHEMISTRY I | PHA | V2023 | 4 | 30 | 45 | PERCENT | 2 | 3 | core | 1 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH1221 | PHYSICOCHEMICAL PRINCIPLES OF PHARMACEUTICALS | PHA | V2023 | 30 | 30 | 45 | PERCENT | 2 | 3 | core | 1 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH1222 | INTRODUCTION TO PHARMACOGNOSY AND TRADITIONAL MEDICINE SYSTEMS | PHA | V2023 | 30 | 30 | 45 | PERCENT | 2 | 3 | core | 1 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
COM1121 | COMMUNICATION SKILLS | PHA | V2023 | 30 | 30 | 45 | PERCENT | 2 | 3 | core | 1 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
DVS1203 | POLITICAL ECONOMY OF AFRICA & DEVELOPMENT | PHA | V2023 | 0 | 45 | 45 | PERCENT | 2 | 3 | core | 1 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
PHS1221 | PHYSIOLOGY II | PHA | V2023 | 15 | 60 | 75 | PERCENT | 2 | 5 | core | 1 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
21 | ||||||||||||||||||||
BCH2121 | MEDICAL BIOCHEMISTRY II | PHA | V2023 | 8 | 45 | 60 | PERCENT | 2 | 4 | core | 2 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BCH2122 | HORMONES, BIOTRANSFORMATIONS AND NUTRITION | PHA | V2023 | 15 | 30 | 45 | PERCENT | 2 | 3 | core | 2 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH2121 | PHARMACEUTICS OF SOLID DOSAGE FORMS | PHA | V2023 | 30 | 30 | 45 | PERCENT | 2 | 3 | core | 2 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH2122 | APPLIED PHYSICAL PHARMACY | PHA | V2023 | 30 | 30 | 45 | PERCENT | 2 | 3 | core | 2 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
DVS2105 | POLITICAL ECONOMY OF UGANDA | PHA | V2023 | 0 | 45 | 45 | PERCENT | 2 | 3 | core | 2 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
MCB2121 | INTRODUCTION TO MICROBIOLOGY | PHA | V2023 | 24 | 48 | 60 | PERCENT | 2 | 4 | core | 2 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
PHA2121 | BASIC PHARMACOLOGY | PHA | V2023 | 30 | 30 | 45 | PERCENT | 2 | 3 | core | 2 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
PHS2121 | PHYSIOLOGY III | PHA | V2023 | 15 | 60 | 75 | PERCENT | 2 | 5 | core | 2 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
22 | ||||||||||||||||||||
BPH2221 | BASIC PHARMACEUTICAL ENGINEERING AND UNIT OPERATIONS | PHA | V2023 | 60 | 22 | 60 | PERCENT | 2 | 4 | core | 2 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH2222 | PHARMACEUTICS OF LIQUID AND SEMISOLID DOSAGE FORMS | PHA | V2023 | 30 | 30 | 30 | PERCENT | 2 | 3 | core | 2 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH2223 | CHEMISTRY AND BIOASSAY OF NATURAL DRUGS AND HEALTH PRODUCTS. | PHA | V2023 | 30 | 45 | 30 | PERCENT | 2 | 4 | core | 2 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
DVS2201 | CITIZENRY, PROFESSIONALISM, GLOBALIZATION AND ENTREPRENEURSHIP | PHA | V2023 | 0 | 45 | 45 | PERCENT | 2 | 3 | core | 2 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
MCB2221 | MICROBIOLOGY II | PHA | V2023 | 34 | 58 | 34 | PERCENT | 2 | 5 | core | 2 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
PAT2221 | GENERAL PATHOLOGY | PHA | V2023 | 60 | 45 | 60 | PERCENT | 2 | 4 | core | 2 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
PHA2221 | SYSTEMIC PHARMACOLOGY | PHA | V2023 | 0 | 39 | 0 | PERCENT | 2 | 3 | core | 2 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
2R | ||||||||||||||||||||
LCP2301 | LEADERSHIP AND COMMUNITY PLACEMENT I | PHA | V2023 | 0 | 45 | 45 | PERCENT | 2 | 3 | core | 2 | R | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
LCP2302 | LEADERSHIP AND COMMUNITY PLACEMENT II | PHA | V2023 | 150 | 75 | 75 | PERCENT | 2 | 5 | core | 2 | R | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
31 | ||||||||||||||||||||
BPH3121 | NON- INSTRUMENTAL METHODS OF PHARMACEUTICAL ANALYSIS | PHA | V2023 | 26 | 32 | 45 | PERCENT | 2 | 3 | core | 3 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH3122 | PHARMACEUTICAL CHEMISTRY I | PHA | V2023 | 30 | 30 | 45 | PERCENT | 2 | 3 | core | 3 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH3123 | INTRODUCTION TO PHARMACEUTICAL CARE AND FIRST AID | PHA | V2023 | 30 | 30 | 45 | PERCENT | 2 | 3 | core | 3 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH3124 | BIOPHARMACEUTICS AND BASIC PHARMACOKINETICS | PHA | V2023 | 0 | 45 | 45 | PERCENT | 2 | 3 | core | 3 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH3125 | PHARMACEUTICS OF PARENTERAL PREPARATIONS | PHA | V2023 | 30 | 45 | 60 | PERCENT | 2 | 4 | core | 3 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
CMH1111 | BIOSTATISTICS AND DEMOGRAPHY | PHA | V2023 | 30 | 30 | 45 | PERCENT | 2 | 3 | core | 3 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
CMH3101 | RESEARCH METHODS | PHA | V2023 | 60 | 30 | 60 | PERCENT | 2 | 4 | core | 3 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
PHA3121 | CHEMOTHERAPY, CYTOTOXIC AGENTS AND IMMUNOPHARMACOLOGY | PHA | V2023 | 10 | 40 | 45 | PERCENT | 2 | 3 | core | 3 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
32 | ||||||||||||||||||||
BPH3221 | NATURAL DRUG PRODUCTION, QUALITY CONTROL AND REGULATION | PHA | V2023 | 30 | 45 | 60 | PERCENT | 2 | 4 | core | 3 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH3222 | CLINICAL PHARMACOKINETICS & LABORATORY DATA | PHA | V2023 | 0 | 24 | 45 | PERCENT | 2 | 3 | core | 3 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH3223 | PHARMACEUTICAL CHEMISTRY II | PHA | V2023 | 30 | 45 | 60 | PERCENT | 2 | 4 | core | 3 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH3224 | PHARMACEUTICAL CARE IN NONCOMMUNICABLE DISEASES | PHA | V2023 | 56 | 41 | 75 | PERCENT | 2 | 5 | core | 3 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH3225 | DRUG TARGETING AND DELIVERY SYSTEMS | PHA | V2023 | 12 | 30 | 45 | PERCENT | 2 | 3 | core | 3 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH3226 | INSTRUMENTAL METHODS OF PHARMACEUTICAL ANALYSIS | PHA | V2023 | 30 | 30 | 45 | PERCENT | 2 | 3 | core | 3 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
PHA3221 | CNS PHARMACOLOGY, TOXICOLOGY & THERAPEUTICS | PHA | V2023 | 0 | 50 | 60 | PERCENT | 2 | 4 | core | 3 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
3R | ||||||||||||||||||||
BPH3321 | COMMUNITY PHARMACY AND HOSPITA | PHA | V2023 | 150 | 0 | 75 | PERCENT | 2 | 5 | core | 3 | R | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH3322 | INDUSTRIAL PLACEMENTS | PHA | V2023 | 150 | 0 | 75 | PERCENT | 2 | 5 | core | 3 | R | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH3323 | PROPOSAL WRITING | PHA | V2023 | 150 | 0 | 75 | PERCENT | 2 | 5 | core | 3 | R | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
41 | ||||||||||||||||||||
BPH4121 | IMPORTANT NATURAL PRODUCTS IN CLINICAL USE | PHA | V2023 | 0 | 29 | 0 | PERCENT | 2 | 4 | core | 4 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH4122 | PHARMACEUTICS OF RADIOPHARMACEUTICALS | PHA | V2023 | 30 | 30 | 30 | PERCENT | 2 | 3 | core | 4 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH4123 | VETERINARY PHARMACY PRACTICE | PHA | V2023 | 30 | 30 | 30 | PERCENT | 2 | 3 | core | 4 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH4124 | PHARMACEUTICAL CARE IN COMMUNICABLE DISEASES | PHA | V2023 | 59 | 42 | 59 | PERCENT | 2 | 5 | core | 4 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH4125 | COSMETIC SCIENCE | PHA | V2023 | 30 | 30 | 30 | PERCENT | 2 | 3 | core | 4 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH4126 | CONDUCT OF RESEARCH | PHA | V2023 | 150 | 0 | 150 | PERCENT | 2 | 5 | core | 4 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
MCB4121 | PHARMACEUTICAL MICROBIOLOGY | PHA | V2023 | 30 | 30 | 30 | PERCENT | 2 | 3 | core | 4 | 1 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
42 | ||||||||||||||||||||
BPH4221 | CLINICAL PHARMACY CLERKSHIP | PHA | V2023 | 90 | 0 | 75 | PERCENT | 2 | 75 | core | 4 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH4222 | DRUG DEVELOPMENT AND CLINICAL TRIALS | PHA | V2023 | 12 | 45 | 60 | PERCENT | 2 | 60 | core | 4 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH4223 | PHARMACEUTICAL BIOTECHNOLOGY | PHA | V2023 | 30 | 13 | 60 | PERCENT | 2 | 60 | core | 4 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH4224 | PHARMACEUTICAL REGULATION, LAWS AND ETHICS | PHA | V2023 | 30 | 30 | 45 | PERCENT | 2 | 45 | core | 4 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH4225 | PHARMACEUTICAL MANAGEMENT AND SUPPLY CHAIN | PHA | V2023 | 0 | 45 | 45 | PERCENT | 2 | 45 | core | 4 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH4226 | PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS | PHA | V2023 | 0 | 28 | 45 | PERCENT | 2 | 45 | core | 4 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||
BPH4227 | DISSERTATION WRITING AND DEFENSE | PHA | V2023 | 150 | 0 | 75 | PERCENT | 2 | 75 | core | 4 | 2 | default | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | MR. KALUNGI DICKSON | 20-SEP-2023 | |||